ArticleFrontiers in endocrinology2024
Angiogenic factor-driven improvement of refractory thin endometrium with autologous platelet-rich plasma intrauterine infusion in frozen embryo transfer cycles.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of platelet-rich plasma or plasma rich in growth factors in the treatment of thin endometrium: a systematic review and meta-analysis of randomized controlled trials.Frontiers in endocrinology · 2026Pooled it
- First-in-human pilot trial of G-CSF-mobilised platelet-leukocyte concentrate for severe refractory Asherman syndrome.Frontiers in endocrinology · 2026Trial
- Comparison of the efficacy of single vs. double autologous platelet-rich plasma intrauterine infusion on endometrial receptivity in thin endometrium patients: a prospective randomized controlled trial.Frontiers in endocrinology · 2025Trial
- Intrauterine platelet-rich plasma and subsequent endometrial pathology evaluation in a patient undergoing a frozen embryo transfer cycle: a case report.Journal of assisted reproduction and genetics · 2026Article
- mTORC1 as a metabolic rheostat coordinates hormonal signals and cellular proliferation to sustain endometrial competence.Cellular & molecular biology letters · 2026Article
- Subendometrial platelet-rich plasma injection for refractory thin endometrium: a prospective pilot study.Scientific reports · 2026Article
- Impact of intrauterine infusion of human umbilical cord blood mononuclear cells on reproductive outcomes in patients with thin endometrium undergoing frozen embryo transfer.Frontiers in cell and developmental biology · 2026Article
- Molecular Crosstalk Between Intrauterine hCG and Endometrial Receptivity: Signalling Pathways, Immune Modulation, and Translational Perspectives in IVF.International journal of molecular sciences · 2025Review
- Platelet-Rich Plasma in Reproductive Endocrinology: Mechanisms and Clinical Applications for Ovarian Reserve, PCOS, and Endometrial Receptivity.Biomedicines · 2025Review
- The effect of autologous platelet-rich plasma intrauterine perfusion on pregnancy outcomes of frozen-thawed embryo transfer in patients with chronic endometritis.Frontiers in reproductive health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: A beneficial effect on endometrial thickness (EMT) and improvement of pregnancy outcome after intrauterine infusion of platelet-rich plasma (PRP) has been suggested. This study assessed the effect of intrauterine PRP infusion on live birth rate and obstetrical outcomes and analyzed cytokines that can potentially improve pregnancy outcomes through PRP. Method: This study was a prospective cohort study conducted in a university hospital fertility center. The study included ninety-one patients who had a history of two or more failed Results: The live birth rate in the PRP treatment cycle was 20.9% (19 of 91 patients), significantly superior to the previous cycle without PRP infusion (p < 0.001). The implantation rate was also significantly higher during the PRP treatment cycle (16.4%) compared to the previous cycle (3.1%) (p < 0.001). The mean EMT post-PRP treatment was 6.1 mm, showing a significant increase of 0.8 mm (p < 0.001). Nonetheless, an increase in EMT was also observed in the non-pregnancy group. No adverse effects were reported by patients treated with autologous PRP. Cytokine array analysis confirmed marked increases in well-known pro-angiogenic factors such as Ang-1, EGF, LAP (TGF-b1), MMP-8, PDGF-AA, and PDGF-AB/PDGF-BB. Conclusion: Intrauterine PRP infusion offers a safe and effective treatment for patients with refractory thin endometrium and implantation failures. The angiogenic cytokines present in PRP are the primary drivers of this improvement.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.